AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34461042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-COVID-19 impact analysis
Number of subjects: 1000
Study 33849856 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative dexmedetomidine sedation
Number of subjects: 0
Study 33849856 — intervention group
Group type: COMPARATOR
Intervention: Standard institutional sedation protocols
Number of subjects: 0
Study 32222134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg once daily)
Number of subjects: 5050
Study 32222134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 35415940 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST+EMD
Number of subjects: 45
Study 35415940 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST+EMD+BMDX
Number of subjects: 45
Study 35977769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide 5 mg/kg orally loading dose, then 1.5 mg/kg every 12 hours maintenance dose, titrated to target BGC 2.6‐5.4 mmol/L
Number of subjects: 100
Study 35977769 — intervention group
Group type: COMPARATOR
Intervention: Placebo, equal volume to diazoxide
Number of subjects: 100
Study 34342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel nail polish application
Number of subjects: 40
Study 34342893 — intervention group
Group type: COMPARATOR
Intervention: No polish (control)
Number of subjects: 40
Study 34342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail length (2 to <3-mm and ≥3-mm)
Number of subjects: 40
Study 32361696 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 138
Study 32361696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 33932093 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of apremilast at 20, 30, or 40 mg
Number of subjects: 28
Study 33932093 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of apremilast at 30 mg b.i.d. for 14 days
Number of subjects: 28
Study 33932093 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 28
Study 34334736 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-only protocol
Number of subjects: 0
Study 34334736 — intervention group
Group type: COMPARATOR
Intervention: Mail (postal) only protocol
Number of subjects: 0
Study 34334736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol (web with postal mail follow-up)
Number of subjects: 0
Study 34334736 — intervention group
Group type: COMPARATOR
Intervention: Respondents without email addresses
Number of subjects: 0
Study 35707932 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stitch technique (5 to 8 mm every 5 mm, USP 2-0, single thread HR 26 mm needle)
Number of subjects: 425
Study 35707932 — intervention group
Group type: COMPARATOR
Intervention: Long stitch technique (10 mm every 10 mm, USP 1, double loop, HR 48 mm needle)
Number of subjects: 425
Study 35707932 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stitch technique
Number of subjects: 425
Study 33407130 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme (LMA-S)
Number of subjects: 80
Study 33407130 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 80
Study 33443290 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandaging
Number of subjects: 94
Study 33443290 — intervention group
Group type: COMPARATOR
Intervention: Plaster casting
Number of subjects: 94
Study 34400397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-mode education program for pharmacists (five evidence-based online modules and skills review)
Number of subjects: 97
Study 34400397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-mode education program for pharmacists
Number of subjects: 97
Study 34509954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pazopanib (IP)
Number of subjects: 168
Study 34509954 — intervention group
Group type: COMPARATOR
Intervention: Continuous pazopanib (CP)
Number of subjects: 168
Study 32548811 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI grade-based prognostic nomogram
Number of subjects: 1051
Study 32548811 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ascites, ALBI grade 2–3, serum ɑ-fetoprotein level ≥ 400 ng/mL, total tumor volume ≥ 396 cm3, presence of vascular invasion, poor performance status
Number of subjects: 1051
Study 35304018 — intervention group
Group type: EXPERIMENTAL
Intervention: Education using a rhinoplasty training guide prior to surgery
Number of subjects: 79
Study 35304018 — intervention group
Group type: COMPARATOR
Intervention: Routine plastic surgery procedures (Control)
Number of subjects: 79
Study 33580803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 46
Study 33580803 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 46
Study 34263472 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent softgel capsules (100 mg or 250 mg)
Number of subjects: 181
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise
Number of subjects: 201
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 201
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration exercise
Number of subjects: 201
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration exercise
Number of subjects: 201
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exercise training
Number of subjects: 201
Study 32969699 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline affective response scores
Number of subjects: 201
Study 36103415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation (20 ml/kg bolus, followed by 3 ml/kg/hour)
Number of subjects: 249
Study 36103415 — intervention group
Group type: COMPARATOR
Intervention: Moderate fluid resuscitation (10 ml/kg bolus for hypovolemia or no bolus for normovolemia, followed by 1.5 ml/kg/hour)
Number of subjects: 249
Study 36103415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation
Number of subjects: 249
Study 36103415 — intervention group
Group type: COMPARATOR
Intervention: Moderate fluid resuscitation
Number of subjects: 249
Study 32940732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-congruent (UC) inserts
Number of subjects: 66
Study 32940732 — intervention group
Group type: COMPARATOR
Intervention: Posterior stabilized (PS) inserts
Number of subjects: 66
Study 32046767 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory Care Planning (ACP) intervention delivered by specially trained registered nurses in a primary care setting
Number of subjects: 0
Study 35751772 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose tranexamic acid (TXA): 50 mg/kg, 5 mg/kg/hr
Number of subjects: 62
Study 34225395 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) teaching program
Number of subjects: 107
Study 34225395 — intervention group
Group type: COMPARATOR
Intervention: Traditional teacher-centered method
Number of subjects: 107
Study 35123664 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 201
Study 35123664 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 201
Study 35123664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 35123664 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOIT
Number of subjects: 201
Study 35123664 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT
Number of subjects: 201
Study 36126603 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized swallowing rehabilitation twice a day for 10 days
Number of subjects: 68
Study 36126603 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing and health education
Number of subjects: 68
Study 33350756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft intervention
Number of subjects: 0
Study 33350756 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative protocols
Number of subjects: 0
Study 36078233 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐endorphin levels before chemotherapy
Number of subjects: 139
Study 36078233 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐endorphin levels after chemotherapy
Number of subjects: 139
Study 36078233 — intervention group
Group type: COMPARATOR
Intervention: β‐endorphin levels
Number of subjects: 139
Study 36078233 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin levels before chemotherapy
Number of subjects: 139
Study 33331038 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental participation in the care of hospitalized children
Number of subjects: 0
Study 33331038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no parental participation)
Number of subjects: 0
Study 34645654 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE intervention (automated search, pharmacist outreach, patient invitation for medication review)
Number of subjects: 21877
Study 34645654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21877
Study 34645654 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE intervention
Number of subjects: 21877
Study 33306229 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR + TAC
Number of subjects: 90
Study 33306229 — intervention group
Group type: EXPERIMENTAL
Intervention: EVR + CyA
Number of subjects: 90
Study 33306229 — intervention group
Group type: COMPARATOR
Intervention: MPA + TAC
Number of subjects: 90
Study 32036193 — intervention group
Group type: EXPERIMENTAL
Intervention: STan+CTG
Number of subjects: 32
Study 32036193 — intervention group
Group type: COMPARATOR
Intervention: CTG alone
Number of subjects: 32
Study 35689147 — intervention group
Group type: EXPERIMENTAL
Intervention: Current relationship with male partner living with HIV
Number of subjects: 718
Study 35689147 — intervention group
Group type: EXPERIMENTAL
Intervention: No current relationship with only female past partners
Number of subjects: 718
Study 35689147 — intervention group
Group type: EXPERIMENTAL
Intervention: No current relationship
Number of subjects: 718
Study 32602588 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care nursing intervention (three home visits by nurses in 1 month after hospital discharge)
Number of subjects: 48
Study 32602588 — intervention group
Group type: COMPARATOR
Intervention: Control group (relying on the service network)
Number of subjects: 48
Study 32557260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate hydrate (ZAH; zinc, 50 mg/day)
Number of subjects: 91
Study 32557260 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (PPZ; zinc, 34 mg/day)
Number of subjects: 91
Study 32557260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dialysis SCre level ≥ 10.0 mg/dL
Number of subjects: 91
Study 34470119 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder system (laboratory requisition and telephone reminder)
Number of subjects: 75
Study 34470119 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 75
Study 34470119 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder system (public insurance)
Number of subjects: 75
Study 34470119 — intervention group
Group type: COMPARATOR
Intervention: Routine care (public insurance)
Number of subjects: 75
Study 34470119 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed test
Number of subjects: 75
Study 33351892 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 627
Study 33351892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 32729120 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CBD
Number of subjects: 30
Study 32729120 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 30
Study 32729120 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg CBD
Number of subjects: 30
Study 32729120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35697050 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant protein vaccine (high dose)
Number of subjects: 0
Study 35697050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34203025 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS group (n = 27)
Number of subjects: 55
Study 34203025 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 55
Study 34332895 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lotilaner ophthalmic solution, 0.25%
Number of subjects: 60
Study 34332895 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 60
Study 32281592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PR) intervention in the dorsal root ganglion
Number of subjects: 50
Study 32281592 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 50
Study 34668065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Otosporin®
Number of subjects: 20
Study 34668065 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 20
Study 34668065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Otosporin® and placebo)
Number of subjects: 20
Study 34615514 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath analysis using gas chromatography coupled with ion mobility spectrometry and machine learning in OSCC patients
Number of subjects: 105
Study 34615514 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 105
Study 32799781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bird Tales program
Number of subjects: 0
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-proteomic approach (including troponin and BNP)
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-proteomic biomarkers (troponin, BNP, TRAILR2, Gal-9, FGF23, AMBP)
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and Gal-9
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin, FGF23, AMBP
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-proteomics
Number of subjects: 5131
Study 32789678 — intervention group
Group type: EXPERIMENTAL
Intervention: Final biomarker selection added to clinical model
Number of subjects: 5131
Study 32712884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus daclatasvir for 3 months
Number of subjects: 0
Study 32712884 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir, ombitasvir and ritonavir plus ribavirin for 3 months
Number of subjects: 0
Study 32712884 — intervention group
Group type: COMPARATOR
Intervention: IL28B genotypes correlation with sustained virologic response
Number of subjects: 0
Study 32712884 — intervention group
Group type: COMPARATOR
Intervention: Baseline fibroscan scores
Number of subjects: 0
Study 35469110 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suctioning
Number of subjects: 60
Study 35469110 — intervention group
Group type: COMPARATOR
Intervention: Simple compression
Number of subjects: 60
Study 33970012 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-educative nursing intervention programme
Number of subjects: 168
Study 35916680 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS-guided biopsy (CEUS-GB)
Number of subjects: 2056
Study 35916680 — intervention group
Group type: COMPARATOR
Intervention: US-guided biopsy (US-GB)
Number of subjects: 2056
Study 33372533 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 33372533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease (CVD)
Number of subjects: 0
Study 35122085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use >60 days/year
Number of subjects: 14315
Study 35122085 — intervention group
Group type: COMPARATOR
Intervention: Aspirin use ≤60 days/year
Number of subjects: 14315
Study 35122085 — intervention group
Group type: COMPARATOR
Intervention: Not walking regularly (reference group)
Number of subjects: 14315
Study 35122085 — intervention group
Group type: COMPARATOR
Intervention: Walking <2 mph
Number of subjects: 14315
Study 35122085 — intervention group
Group type: COMPARATOR
Intervention: Walking ≥2-2.9 mph
Number of subjects: 14315
Study 35122085 — intervention group
Group type: COMPARATOR
Intervention: Walking ≥3 mph
Number of subjects: 14315
Study 32220414 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine initiation (8 mg sublingual buprenorphine or 8-2 mg sublingual buprenorphine/naloxone)
Number of subjects: 6523
Study 32220414 — intervention group
Group type: COMPARATOR
Intervention: Screening for substance misuse
Number of subjects: 6523
Study 35085874 — intervention group
Group type: EXPERIMENTAL
Intervention: early adenotonsillectomy (eAT)
Number of subjects: 397
Study 35085874 — intervention group
Group type: COMPARATOR
Intervention: watchful waiting with supportive care (WWSC)
Number of subjects: 397
Study 32926851 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training on a walking track with different surfaces (WTDS) (n=28) for 30 min/d, 5 d/wk over 4 weeks
Number of subjects: 54
Study 32926851 — intervention group
Group type: COMPARATOR
Intervention: Overground walking training (n=26) for 30 min/d, 5 d/wk over 4 weeks
Number of subjects: 54
Study 32926851 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training on a walking track with different surfaces (WTDS) (n=28)
Number of subjects: 54
Study 32926851 — intervention group
Group type: COMPARATOR
Intervention: Overground walking training (n=26)
Number of subjects: 54
Study 34578900 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) toddler milk formula (30 g protein, 10 g fat)
Number of subjects: 27
Study 34578900 — intervention group
Group type: COMPARATOR
Intervention: Low Protein (LP) toddler milk formula (7 g protein, 20 g fat)
Number of subjects: 27
Study 34578900 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) toddler milk formula
Number of subjects: 27
Study 34578900 — intervention group
Group type: COMPARATOR
Intervention: Low Protein (LP) toddler milk formula
Number of subjects: 27
Study 35968550 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa roxburghii Tratt juice (RRTJ)
Number of subjects: 106
Study 35968550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 33023997 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory therapist‐driven oxygen titration after an electronic alert
Number of subjects: 195
Study 33023997 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (titration based on physician order)
Number of subjects: 195
Study 33408009 — intervention group
Group type: EXPERIMENTAL
Intervention: IV1 (single intravenous dose of 15 mg TXA/kg prior to skin incision)
Number of subjects: 400
Study 33408009 — intervention group
Group type: EXPERIMENTAL
Intervention: IV2 (two intravenous doses of 15 mg TXA/kg: one prior to skin incision and one 6 hours after)
Number of subjects: 400
Study 33408009 — intervention group
Group type: COMPARATOR
Intervention: TOP (2 g TXA in 50 ml of saline irrigated topically at the end of surgery)
Number of subjects: 400
Study 33408009 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (combined IV1 and TOP regimens)
Number of subjects: 400
Study 33408009 — intervention group
Group type: COMPARATOR
Intervention: IV1, IV2, COMB
Number of subjects: 400
Study 33408009 — intervention group
Group type: COMPARATOR
Intervention: IV1, IV2, COMB, TOP
Number of subjects: 400
Study 36123259 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU/kg Omtv + vaccine
Number of subjects: 240
Study 36123259 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/kg Omtv + vaccine
Number of subjects: 240
Study 36123259 — intervention group
Group type: COMPARATOR
Intervention: 20 IU/kg HRIG + vaccine
Number of subjects: 240
Study 36123259 — intervention group
Group type: COMPARATOR
Intervention: Placebo + vaccine
Number of subjects: 240
Study 32867758 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone instruction using an application
Number of subjects: 53
Study 32867758 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based instruction
Number of subjects: 53
Study 33571687 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer recruitment
Number of subjects: 1487
Study 33571687 — intervention group
Group type: COMPARATOR
Intervention: Facebook Ads
Number of subjects: 1487
Study 33571687 — intervention group
Group type: COMPARATOR
Intervention: ResearchMatch
Number of subjects: 1487
Study 32703293 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities for Healthy Living (CHL) intervention
Number of subjects: 0
Study 32703293 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation methods
Number of subjects: 0
Study 32703293 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative data integration
Number of subjects: 0
Study 35604745 — intervention group
Group type: EXPERIMENTAL
Intervention: Marriage checkup (active treatment)
Number of subjects: 244
Study 35604745 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 244
Study 33849953 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaSorin Liaison antigen test
Number of subjects: 414
Study 34863354 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet‐based intervention
Number of subjects: 0
Study 32871923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudi enteric-coated capsules (HEC)
Number of subjects: 240
Study 32871923 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated mesalazine tablets placebo
Number of subjects: 240
Study 34981201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load training with BFR
Number of subjects: 27
Study 34981201 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 27
Study 34610821 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Pender's health promotion model
Number of subjects: 80
Study 34610821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80